Allopurinol Impact on Mineral and Bone Metabolism in Chronic Kidney Disease Patients
This study aims to evaluate the impact of Allopurinol treatment on mineral and bone metabolism in patients with Chronic Kidney Disease, specifically focusing on increasing 1,25 dihydroxivitamin D and alpha Klotho levels, while reducing FGF-23.
Allopurinol
Urogenital Diseases+13
+ Calcinosis
+ Calcium Metabolism Disorders
Treatment Study
Summary
Study start date: March 1, 2021
Actual date on which the first participant was enrolled.This study focuses on understanding the impact of a medication called Allopurinol on bone and mineral health in patients with Chronic Kidney Disease (CKD). The research takes place in Sao Paulo, Brazil, and involves patients in stages 3, 4, or 5 of CKD who are under conservative management at the Nephrology Service of Hospital das Clinicas HCFMUSP. The study aims to find out if Allopurinol can improve bone health and mineral balance in these patients, which could lead to better care and quality of life for individuals living with CKD. During the study, patients receive either Allopurinol or a placebo (a pill with no active ingredients) for 3 months. The effects of these treatments on bone health and mineral balance are measured through changes in specific substances in the body, such as 1,25 dihydroxivitamin D, FGF-23, and alpha Klotho. Patients are monitored by the same physician throughout the study, and any adverse effects are recorded.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.50 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: stage 3, 4 or 5 CKD on conservative management \- Exclusion Criteria: * allergy to allopurinol * current treatment with allopurinol * Gout
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorGroup II
PlaceboStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location